PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
Volume: 9, Issue: 4, Pages: 201 - 206
Published: Oct 28, 2016
Abstract
Tumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1). Checkpoint inhibitors (ICI) provide encouraging therapeutic results in non-small cell lung cancers (NSCLC) and may soon be used in 2nd or 1st line therapy. Currently PD-L1 immunohistochemistry (IHC) expression assessed on tumour cells is used as a predictive biomarker, since...
Paper Details
Title
PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
Published Date
Oct 28, 2016
Volume
9
Issue
4
Pages
201 - 206
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History